Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adsorbed acellular diphtheria, tetanus, pertussis, inactivated poliovirus, and Haemophilus influenzae type b pentavalent combined vaccine
- Development stage
- Unknown
- Lead developer
- Shenzhen Kangtai Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The adsorbed acellular diphtheria, tetanus, pertussis, inactivated poliovirus, and Haemophilus influenzae type b pentavalent combined vaccine is a multi-antigen biologic developed by **Shenzhen Kangtai Biological Products Co., Ltd. (Biokangtai)**. This pediatric combination vaccine is designed to provide simultaneous protection against five major infectious diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, and invasive disease caused by *Haemophilus influenzae* type b (Hib). The formulation utilizes acellular pertussis antigens (rather than whole-cell components) and inactivated poliovirus (IPV) types 1, 2, and 3, alongside diphtheria and tetanus toxoids and a Hib conjugate, all adsorbed onto an aluminum-based adjuvant to enhance immunogenicity. By combining these five components into a single injection, the vaccine aims to simplify the immunization schedule for infants and young children, improving compliance and reducing the number of required clinical visits. It is currently in Phase 2 clinical development in China, with reports indicating it is approaching Phase 3.
- Other names
- DTaP-IPV-Hib vaccineBiokangtai pentavalent vaccineAdsorbed acellular DTP-IPV-Hib pentavalent combined vaccine
02
Targets
Pertactin / fimbrial pertussis surface antigensDiphtheria toxinFHA (Filamentous hemagglutinin)
Beyond the preview
Go deeper on adsorbed acellular diphtheria, tetanus, pertussis, inactivated poliovirus, and Haemophilus influenzae type b pentavalent combined vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adsorbed acellular diphtheria, tetanus, pertussis, inactivated poliovirus, and Haemophilus influenzae type b pentavalent combined vaccine.